Trials / Completed
CompletedNCT07139054
68Ga-FAPI-46 PET/CT for the Prediction of Clinical Response to Neoadjuvant Therapy in Nasopharyngeal Carcinoma Patients
68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Prediction of Clinical Response to Neoadjuvant Therapy in Nasopharyngeal Carcinoma Patients: A Prospective Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 31 (actual)
- Sponsor
- The First Affiliated Hospital of Xiamen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- —
Summary
The goal of this clinical trial is to learn about the prediction of clinical response to neoadjuvant therapy in nasopharyngeal carcinoma patients via 68Ga-FAPI-46 PET/CT. The main question it aims to answer is: Can 68Ga-FAPI-46 PET/CT be used to evaluate the therapeutic response of neoadjuvant therapy for nasopharyngeal carcinoma？ The researchers will compare the correlation between the parameters obtained after three 68Ga-FAPI-46 PET/CT scans and the treatment response after neoadjuvant and neoadjuvant combined with concurrent chemoradiotherapy. Participants will: Undergo three 68Ga-FAPI-46 PET/CT scans before starting treatment, after neoadjuvant therapy, and after concurrent chemoradiotherapy
Conditions
Timeline
- Start date
- 2024-01-31
- Primary completion
- 2025-03-31
- Completion
- 2025-08-10
- First posted
- 2025-08-24
- Last updated
- 2025-08-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07139054. Inclusion in this directory is not an endorsement.